Characterization of KPC-160, a novel Ω-loop-deleted KPC variant on a dual-copy plasmid that confers cefiderocol

Yuxuan Liu1,2, Hanxu Hong1,2, Qisen Huang1

  • 1Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Insights

A new carbapenemase variant, KPC-160, causes cefiderocol (FDC) resistance in Klebsiella pneumoniae due to a specific deletion. This finding highlights the need for ongoing genomic surveillance to combat antimicrobial resistance.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Genetics

Background:

  • Carbapenemase-type carbapenemases (KPC) are a significant cause of Klebsiella pneumoniae resistance.
  • Cefiderocol (FDC) is a cephalosporin effective against many KPC producers, but emerging variants threaten its utility.

Purpose of the Study:

  • To identify and functionally characterize a novel KPC variant, KPC-160, responsible for cefiderocol (FDC) resistance.
  • To elucidate the mechanism by which KPC-160 confers FDC resistance.

Main Methods:

  • Whole-genome sequencing and antimicrobial susceptibility testing were used to identify and define the resistance profile of the KPC-160 variant.
  • Carbapenemase activity assays, enzyme kinetics, and molecular modeling were employed to understand the functional mechanism of resistance.
  • Conjugation assays and plasmid analysis determined the genetic context and transferability of the blaKPC-160 variant.

Main Results:

  • A novel KPC variant, KPC-160, with a two-amino acid deletion (ΔGlu167-Leu168) in the Ω-loop was identified in a clinical Klebsiella pneumoniae isolate (K1661).
  • KPC-160 conferred significant FDC resistance (16-fold higher MIC than KPC-2) and multidrug resistance.
  • Molecular modeling indicated the deletion stabilizes FDC binding in the active site, leading to resistance.
  • The blaKPC-160 variant was found on an IncFIB(K) plasmid in dual IS26-flanked copies, showing efficient transfer.

Conclusions:

  • The blaKPC-160 deletion variant confers clinically relevant FDC resistance through enhanced FDC binding and compromised inhibition.
  • The presence of blaKPC-160 on a highly transmissible, dual-copy plasmid poses a risk for rapid dissemination.
  • Continuous genomic surveillance for emerging KPC variants is crucial for preserving FDC's clinical effectiveness.